Warby Parker Inc. (WRBY) Q3 2025 10-Q Quarterly Report

Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Ophthalmic GoodsSEC EDGAR

Warby Parker Inc. (WRBY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Warby Parker Inc. Q3 2025 10-Q Analysis

Risk Factors

  • New trade tariff risk from recent U.S. tariff increases on imports from China, Italy, Vietnam, Japan raising product costs
  • Most material update: heightened tariffs causing cost escalation uncertainty and potential margin compression or price hikes
+3 more insights

Warby Parker Inc. Q3 2025 Quarterly Financials
XBRL

Revenue

$222M

+15.2% YoY +3.4% QoQ

Net Income

$6M

+244.3% YoY +435.3% QoQ

Gross Margin

54.1%

-38bp YoY +114bp QoQ

Operating Margin

1.6%

+505bp YoY +372bp QoQ

Net Margin

2.6%

+477bp YoY +347bp QoQ

ROE

1.6%

Total Assets

$707M

EPS (Diluted)

$0.05

+266.7% YoY +350.0% QoQ

Operating Cash Flow

$18M

-34.1% YoY -55.3% QoQ

Source: XBRL data from Warby Parker Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Warby Parker Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.